CytoCore Ready to Manufacture e2(TM) Collector.Non-Invasive Medical Device Enhances Accuracy of Cervical Cancer Cervical Cancer Definition Cervical cancer is a disease in which the cells of the cervix become abnormal and start to grow uncontrollably, forming tumors. Screening Samples CHICAGO -- CytoCore Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYCR), a late-stage bio-scientific research company advancing tools and testing for the early detection and diagnosis of deadly reproductive cancers, today announced that it is ready to start manufacturing its cutting-edge e2 Collector[TM] sample retrieval device. With a prototype model and engineering design refined through a thorough manufacturing development process, CytoCore is ready this month to start production on the e2 Collector for clinical testing, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. review and subsequent distribution worldwide. The sample-collecting device's innovative handle and balloon disposable component offer excellent performance comparison and distinct patient comfort improvement over the brush-and-spatula method currently used by doctors in taking routine Pap samples for the early screening of cervical cancer. "Through the prototype development, pre-production engineering and tooling-up phases, we are now ready to deliver a truly high-quality, low-cost medical product that will enhance the quality of cell sampling for Pap and HPV HPV human papillomavirus. HPV abbr. human papilloma virus Human papilloma virus (HPV) tests. This simple product is capable of offering enhanced early detection and diagnosis, and, therefore, will contribute to the potential savings of the lives of many women," said Dr. Augusto Ocana, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CytoCore. The Company's immediate focus will be on a clinical trial, which should be completed within 90 days, with FDA review to follow shortly afterward and sales and distribution agreements anticipated both within the United States and abroad. "We expect to be ready for volume production by mid-summer, producing up to 800,000 units a month on one shift," Dr. Ocana said. "With our cash-flow break-even point break-even point - In the process of implementing a new computer language, the point at which the language is sufficiently effective that one can implement the language in itself. at a volume of between 80,000 and 100,000 units per month, we're projecting a very strong return right out of the gate." The first significant upgrade to the Pap test Pap test, Pap smear, or Papanicolaou test (păp'ənē`kəlou), medical procedure used to detect cancer of the uterine cervix. in 50 years, the e2 Collector is a small disposable balloon device designed to enhance the thoroughness and consistency of cell collections for the Pap smear Pap smear or Papanicolaou smear Sample of cells from the vagina and cervix of the uterus for laboratory staining and examination to detect genital herpes and early-stage cancer, especially of the cervix. Developed by the Greek-born U.S. and HPV test screenings performed annually on some 180 million women worldwide. The e2 Collector is designed to significantly improve both the patient's comfort and physician's confidence in the collection procedure. For further information about the e2 Collector and CytoCore's full suite of products for the diagnoses and treatment of reproductive cancers, visit www.CytoCoreInc.com. For further information about cervical cancer, visit the American Cancer Society's webpage: www.cancer.org. About CytoCore Inc. CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial endometrial /en·do·me·tri·al/ (en?do-me´tre-il) pertaining to the endometrium. endometrial, n relating to the end-ometrium or cavity of the uterus. , and other cancers. The InPath[TM] System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer uterine cancer Malignant tumour of the uterus. Cancers affecting the lining of the uterus (endometrium) are the most common cancers of the female reproductive tract. screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath[TM] System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion